Risk of short-term prostate-specific antigen recurrence and failure in patients with prostate cancer
1. For patients with unfavorable nonmetastatic prostate cancer aged above 70 years, PSA levels above 10 ng/mL, and Gleason scores ...
1. For patients with unfavorable nonmetastatic prostate cancer aged above 70 years, PSA levels above 10 ng/mL, and Gleason scores ...
1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade 3 ...
1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade ...
1. 3-year event-free survival rates were significantly greater in the 18F-fluciclovine-PET group compared to conventional imaging. 2. Adverse reactions and ...
1. Radiolabeled Lutetium-177 offered greater PSA response versus current standard of care, cabazitaxel. 2. Fewer grade 3-4 adverse events occurred ...
1. In this randomized controlled trial, men who were screened with a single PSA test had higher diagnoses of prostate ...
1. PSA screening was associated with a reduction in risk for death from prostate cancer. 2. No differences in the ...
1. In this cross-sectional study of veteran men across the USA, the rate of prostate-specific antigen (PSA) screening amongst men ...
1. In a cross-sectional analysis of a nationally administered survey in the United States of men undergoing prostate specific antigen ...
Image: PD 1. Subjects undergoing annual prostate-specific antigen (PSA) testing for 6 years and annual digital rectal examination (DRE) for ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.